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Abstract The ‘Bridging medicine and biomedical technology’ special all-congress session 
took place for the first time at the OSA Biophotonics Congress: Optics in Life Sciences in 
2017 
(http://www.osa.org/enus/meetings/osa_meetings/optics_in_the_life_sciences/bridging_medic
ine_and_biomedical_technology_specia/). The purpose was to identify key challenges the 
biomedical scientists in academia have to overcome to translate their discoveries into clinical 
practice through robust collaborations with industry and discuss best practices to facilitate and 
accelerate the process. Our paper is intended to complement the session by providing a deeper 
insight into the concept behind the structure and the content we developed. 
© 2017 Optical Society of America 
OCIS codes: (170.0170) Medical optics and biotechnology; (170.1870) Dermatology; (170.4470) Ophthalmology; 
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Introduction 
Translational research has evolved over the last decade into a new science encompassing 
many scientific and engineering disciplines, medicine, team science, project management and 
partnership development with industry [1,2]. Its promise is the ability to carry the benefits of 
new discoveries across fundamental research, proof-of-concept and development stages to 
accelerate transfer of novel and affordable diagnostics and therapeutics to patient care. 
Success is determined by two factors: (i) relevant and well-defined practical problems to be 
solved; and (ii) the engagement, at appropriate stages, of clinicians, scientists and engineers in 
academia with industry. 
The field of biomedical optics and biophotonics has a highly successful forty year track 
record of performing original and translational research that led to laser surgery, light-
activated therapies, optical diagnostics and imaging and the emergence of new light-based 
technologies that can sense, monitor and manipulate biological processes in the human body 
[3,4]. Novel models to facilitate and accelerate the translation process, creative mechanisms 
to support problem-driven research work, innovative education and training programs have 
been initiated and pioneered in this field [1,3,5,6]. 
The concept 
Despite growing awareness of the significance of translational research and the progress that 
has been made to support it, many challenges remain. Academia and industry are both 
essential in fulfilling the mission of promoting new diagnostics and treatments to alleviate 
burden of human disease. In our experience, one major factor that could enhance the ability of 
academia to bridge with industry and engage in productive partnerships is a more complete 
definition of the problem to be solved at a project’s conception. Key questions need to be 
asked in order to address this limitation. How and at what stage of their research do scientists 
and engineers engage the dialogue with clinicians? How do clinicians identify and assess 
technologies that can solve their problems? And, how do clinicians, scientists and engineers 
together define a relevant solution, design and perform the proper proof-of-concept 
experiments and then engage with industry technology development partners? 
At the Wellman Center for Photomedicine (WCP), one of the five thematic research 
centers at Massachusetts General Research Institute, we have a long tradition of encouraging 
and supporting translational research stemming from a culture that embraces the potential of 
light and optical techniques to impact human health [3]. 
One model to bridge academia with industry that we pilot at the WCP is targeting the 
early stage translation of a new idea from fundamental research to proof-of-concept. Figure 1 
illustrates the problem-driven research planning phase. The goal is to have the project clinical 
lead and scientific/engineering lead take a systematic approach together to understand the 
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practical problem to be solved, formulate the required clinical specifications and identify 
possible solutions and technologies to be tested. By working in concert from the beginning 
through intensive and synergistic interaction, various innovative technologies can be 
developed and applied to solve the specific clinical problem. Figure 2 depicts the working 
flow in the first phase of research planning followed by the second phase including 
manufacturing of the prototype and performance of the proof of concept experiments. The 
outcome of this second phase is critical for a successful transition to the development stage of 
translation, therefore our objective is to engage with industry partners for both prototype 
manufacturing and proof of concept experimental work. 
Fig. 1. Problem-driven research planning. 
Unmet clinical 
need 
Clinician 
Possible 
approaches 
Selec on and 
requirements 
Prototype 
Scien st/ 
Engineer 
Clinician 
Proof of Concept 
Scien st/ 
Engineer 
Scien st/ 
Engineer 
Clinician 
Academia Academia & Industry 
Fig. 2. Early stage translation working flow from problem-driven research planning 
to application relevant proof-of-concept experiments conception and performance. 
Examples 
To illustrate the concept, we selected two concrete examples of important clinical problems in 
dermatology and ophthalmology that we are trying to solve. 
Dermatology 
Problem 
Cellulitis is a bacterial infection of the skin that presents with expanding redness, swelling, 
pain, and warmth. Cellulitis affects 14.5 million Americans annually at a cost of $3.7 billion 
dollars [7,8]. Unfortunately, over 30% of patients with ‘cellulitis’ are actually misdiagnosed 
[9]. These patients are unnecessarily admitted to the hospital, inappropriately treated with 
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antibiotics and subsequently at risk for antibiotic-related complications such as anaphylaxis or 
Clostridium dificile infection [9]. 
Currently, there are no objective diagnostics for cellulitis [10]. Standard blood lab tests 
are neither sensitive nor specific. Bacterial cultures using standard microbiology methods, 
from either skin and blood, are rarely positive and take 24-48 hours for results. As such, 
clinicians typically make the diagnosis of cellulitis based on history and physical exam alone. 
However, given the many skin conditions that mimic cellulitis (collectively known as 
‘pseudocellulitis’), history and physical exam frequently leads to misdiagnosis. Therefore, 
novel objective diagnostics for differentiating cellulitis from pseudocellulitis are needed to 
improve patient care and reduce unnecessary healthcare costs. 
Specs 
Any potential novel diagnostic for cellulitis must meet various internal and external 
constraints. The ‘default’ for clinicians when they see spreading redness, swelling, pain, and 
warmth of the skin is to diagnose cellulitis. This ensures they treat all patients with cellulitis 
(high sensitivity), however they over treat at least 30% (low specificity). Therefore, accuracy 
is a priority, requiring high sensitivity to catch all patients with cellulitis but also high 
specificity to prevent misdiagnosis. Further, the diagnostic needs to provide an ‘answer’ 
rapidly, ideally within 1-2 hours or less of patient presentation to the Emergency Department 
(ED). This timing fits within the flow of a busy ED, allowing them to discharge patients and 
clear valuable beds. In that regard, the diagnostic must be point-of-care to allow treating 
providers to triage their patients and make the decision whether to provide antibiotics or not. 
The tool should be easy to use, requiring only minimal training, thereby maximizing adoption 
and use across physicians and physician-extenders (i.e. nurses, medical assistants, etc.). 
Finally, a new diagnostic should be relatively low cost. 
Solutions 
Dermatologists rely extensively on their visual diagnostic acumen; however, this does not 
scale well given the limited number of providers. In regard to the problem of cellulitis 
misdiagnosis, we want to investigate various non-invasive optical modalities to assess skin 
hemodynamic and metabolic parameters. To accomplish this, we need expertise in 
biophotonics, thermal heat transfer, data processing, machine learning, and mathematical 
modeling. This requires establishing collaborations with biomechanical engineers, electrical 
engineers, computer engineers, and biostatisticians. Recently we have developed a predictive 
model using skin thermal imaging [11]. Utilizing the temperature difference between the 
affected area and unaffected area of skin in patients with presumed cellulitis at the time of 
emergency room presentation, we demonstrate an accuracy of 87.5% in a validation cohort. 
We are currently exploring several additional optical modalities to further enhance the 
accuracy of our thermal imaging model. We anticipate that these diagnostic tools will provide 
valuable data points not available through visual exam alone. Our prototypes and models are 
currently being validated in larger clinical proof of concept studies. 
Ophthalmology 
Problem 
In ophthalmology, the development of short-sightedness (myopia) is an increasingly common 
problem with more than 2.5 billion estimated to be affected worldwide by 2020 [12]. Myopia 
is a pathologic and irreversible elongation of the eye. Studies in Asian college students found 
a prevalence of 95% for myopia and 25% for high myopia (the most severe form) [13]. 
Unfortunately, high myopic patients are severely affected by this elongation of the eye with a 
60-fold increased risk for developing a retinal detachment or other late-onset consequence
compared to normal eyes [14]. Treatment for myopia includes optical aids, such as glasses or
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contact lenses, and LASIK or other refractive procedures [15]. However, these strategies only 
treat the symptoms and not the cause of the disease. Neither the underlying pathologic 
mechanism of axial elongation [16] nor the long-term consequences that accompany it are 
addressed by current solutions. Prior surgical approaches to halt the axial growth, like 
posterior scleral reinforcement, have failed [17] and a pharmaceutical approach using topical 
application of atropine to break the feedback mechanism of axial elongation demonstrated 
only limited clinical success [18]. 
Specs 
One promising approach to prevent the axial elongation process is scleral crosslinking, in 
which the sclera (surrounding tissue of the eye globe) is artificially stiffened in order to 
prevent axial growth [19]. The increase in stiffness is achieved by a light activated dye, which 
generates radicals and subsequently induces new covalent bonds within and between collagen 
molecules [20]. While we recognized the potential benefits of scleral crosslinking, the major 
barrier in previous studies was the invasive method required to guide light onto the dye-
soaked sclera due to the eye’s location inside the orbit. Before brainstorming possible 
solutions to this problem, we determined that the clinical requirements of any suitable 
solution must include a homogeneous irradiation profile directed only towards sclera, the 
ability to use different wavelengths and irradiances, thin dimensions, minimal heat 
development and biocompatibility. 
Solutions 
Utilizing the clinical input, a team of scientists and engineers in biophysics, photochemistry, 
and biomedical engineering investigated potential approaches and developed feasible 
prototypes for clinical use in humans. A promising result came with the development of 
flexible waveguides in which light was coupled by means of a fiber and then homogeneously 
transmitted onto the sclera. First, prototypes were built and basic experiments were conducted 
[21], and currently an in vivo rabbit proof of concept study investigating the feasibility and 
efficacy of the light delivery system is underway at WCP. Further, during profound 
discussions, the idea came up of how to identify possible patients which are in need of this 
artificial stiffening. This resulted in our next project to develop a diagnostic device for 
myopia, which is under investigation at the moment at WCP. 
Conclusion and perspective 
These two examples illustrate the emergence of clinically initiated research projects. In both 
cases, important problems have been identified by clinicians during their current practice. In 
dermatology, novel diagnostics for cellulitis are needed in order to decrease the high 
misdiagnosis rate, prevent unnecessary hospitalizations and reduce overuse of antibiotics. In 
ophthalmology, a therapeutic strategy to stop myopia progression and therefore prevent high 
myopia development and its severe long-term effects is required. Solutions to either of these 
problems depend on the assemblage of multiple novel technologies. More importantly, the 
solutions rely on scientists and engineers with multidisciplinary background and expertise in 
fields such as biomedical optics, biophysics, photochemistry, biology, biomedical 
engineering, and biomechanics to actively engage in dialogue with their clinician colleagues 
to first understand the problem and then consistently plan for relevant proof-of-concept 
experiments and successful partnerships with industry. 
Over the next decade, translational research will become an essential mechanism to seed 
and sustain future innovation in academia, bringing better and more cost effective new 
treatments and diagnostics to patients in need. To this effect and based on the continuous 
increase of biomedical optics and photonics technologies worldwide, scientists and engineers 
will have tremendous opportunities to engage with clinicians and patients and establish solid 
partnerships with industry. Innovative training programs in translational sciences will lay the 
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ground work for an intellectual home where new generations of scientists, engineers and 
clinicians from academia will be able to consistently reach out to their peers in industry to 
solve important problems in medicine and human health. 
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